Maryam Soleimani

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Renal Cell Carcinoma

Genome Wide Identification

Top Venues

Future oncology (London, England)

Current oncology reports

This page only lists publications with an associated author ORCID identifier.

Publications

Lauren Curry, Maryam Soleimani
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future oncology (London, England) 20 (18) (2024)
Lauren Curry, Maryam Soleimani
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future oncology (London, England) 20 (18) (2024)
Lauren Curry, Maryam Soleimani
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future oncology (London, England) (2024)
Lauren Curry, Maryam Soleimani
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future oncology (London, England) 20 (18) (2024)
Lauren Curry, Maryam Soleimani
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future oncology (London, England) (2024)
Maryam Soleimani, Christian Kollmannsberger, Lucia Nappi
Emerging Role of Biomarkers in Testicular Germ Cell Tumors. Current oncology reports 24 (4) (2022)
Maryam Soleimani, Lucia Nappi, Christian K Kollmannsberger
Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. Future oncology (London, England) 16 (36) (2020)